The rising geriatric population and the adoption of unhealthy lifestyles has increased the risks of liver cancer, which is expected to drive the growth of the Egypt Liver Cancer Therapeutics market in the upcoming five years.
According to TechSci report on, “Egypt Liver Cancer Therapeutics Market – By Region, Competition Forecast & Opportunities, 2027”, the Egypt Liver Cancer Therapeutics market may flourish with an impressive CAGR during the forecast period of 2023-2027, on the backbone of the rising burden of liver cancer in Egypt. The rising risk of liver cancer can be attributed to unhealthy lifestyle choices such as smoking, high alcohol consumption, junk eating, sedentary lifestyle leading to excess body weight, and other metabolic disorders. According to a credible source, 27,895 new cases of liver cancer were recorded in Egypt, in 2020. As a result, the demand for liver cancer therapeutic drugs is rising at a rapid rate. Apart from this, the increasing research and development activities in the development of new therapeutics for liver cancer are also providing lucrative growth opportunities to the market. For instance, targeted therapies are increasingly being preferred by healthcare professionals as they target the proteins that control how cancer cell grows, spread, and divide. As researchers are learning more about the DNA changes and proteins that lead to cancer, they are able to get better insights and deliver treatments that target these proteins. Moreover, the rising support from the governments in terms of investment in the healthcare sector to make healthcare services affordable and easily accessible is expected to propel the market for liver cancer therapeutics in Egypt.
Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on “EGYPT LIVER CANCER THERAPEUTICS MARKET“
The Egypt Liver Cancer Therapeutics market is segmented by type, therapy, end user, competitional landscape, and regional distribution. Based on type, the market is further segmented into hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Among these, hepatocellular carcinomas (HCC) are expected to be the fastest growing segment over the forecast period. This is primarily because HCC is the most common form of liver cancer, which usually occurs in people suffering from chronic liver diseases like cirrhosis. Globally also, HCC is one of the major causes of cancer-related deaths. Moreover, several research studies confirmed that people suffering from hepatocellular carcinoma are at a much higher risk of contracting the infection. As a result, hepatocellular carcinoma is expected to lead the segment and propel the Egypt liver cancer market over the coming years.
By therapy, the market is bifurcated into targeted therapy, radiation therapy, immunotherapy, chemotherapy, and others. The chemotherapy segment has held a significant share over the past years, and it is projected to remain dominant over the coming years. This is because chemotherapy uses drugs to kill rapidly growing cancer cells. This therapy is administered through veins in the patient’s arm or is given in pill form, or both.
By end user, the market is divided between hospitals & clinics, ambulatory care, and others. Among these, the hospitals & clinics segment is expected to hold the largest market share over the coming years. This is primarily because hospitals usually have fully developed infrastructure with technologically advanced medical devices and equipment required to perform the stent surgery. Moreover, hospitals and clinics offer better after-surgery care due to the presence of highly skilled professionals and nursing staff. In line with this, the rising focus on upgrading the healthcare infrastructure is expected to fuel this segment of the Egypt Liver Cancer Therapeutics market.
A list of major market players of the Egypt Liver Cancer Therapeutics market includes:
- Roche Egypt LLC
- Bayer Middle East FZE
- Eli Lilly and Company (Egypt)
- Merck Egypt
- Novartis Egypt
Customers can also request for 10% free customization on this report.
“Rapid advancements in liver cancer therapies are strengthening the market growth. For instance, FDA has recently approved an immunotherapy drug called Atezolizumab Plus Bevacizumab. This drug is used with bevacizumab to treat some patients with advanced liver cancer. Moreover, the Egypt government is continuously taking initiatives to limit liver cancer and allow early detection, to improve the chances of survival in patients. In addition, technological advances in diagnosis and therapeutics to facilitate a higher acceptance rate of liver transplant is also fueling the market growth. The new market players are advised to enter the market with innovative and advanced therapies and therapeutics available at an affordable cost to establish their name in the market. They may also partner with international leaders to expand their customer base,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Egypt Liver Cancer Therapeutics Market By Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Others), By Therapy (Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others) By Region, Competition Forecast & Opportunities, 2027” has evaluated the future growth potential of Egypt Liver Cancer Therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Egypt Liver Cancer Therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com